Mr. Timothy Ko reports

ENTHEON BIOMEDICAL ANNOUNCES EFFECTIVE DATE OF SHARE CONSOLIDATION

Further to the news release dated Feb. 21, 2024, Entheon Biomedical Corp. has confirmed the effective date for the consolidation of one postconsolidation share for every 10 preconsolidation shares.

Effective at the opening on Friday, March 1, 2024, the shares of the company will commence trading on the Canadian Securities Exchange on a consolidated basis. The name and stock symbol share remain the same.

Postconsolidation capitalization:  unlimited common shares with no par value of which approximately 5,908,926 common shares are issued and outstanding

Transfer agent:  Olympia Trust Company

Trading symbol:  ENBI

Cusip No.:  29383X202 (new)

Record date:  March 4, 2024

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.